FilingSEC EDGAR6-K
Trinity Biotech Receives Nasdaq Delisting Notice Due to Market Value Deficiency
· SEC accepted
StageNotice Received
Filing content
The company received a staff determination letter from Nasdaq regarding non-compliance with market value requirements and intends to request a hearing.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…